HROC300 T2 M1 Cells

HROC300 T2 M1 is a human colorectal carcinoma cell line derived from a primary tumor specimen resected from an adult patient within the HROC (Hansestadt Rostock Colorectal Cancer) model collection. The designation “T2” indicates that the tumor was obtained at a second surgical time point, while “M1” denotes the corresponding in vitro model established from this specimen. The HROC platform integrates comprehensive biobanking with standardized generation of patient-derived xenografts (PDX) and permanent low-passage cell lines, enabling molecularly annotated tumor models from consecutive colorectal cancer cases.

Establishment of HROC300 T2 M1 followed a standardized protocol involving mechanical dissociation of freshly resected tumor tissue, filtration to obtain single-cell suspensions, and seeding onto collagen-coated culture plates in defined tumor cell culture medium supplemented with glutamine, antibiotics, and antimycotics. Across the HROC cohort, permanent primary cell lines were generated from approximately 13% of attempted colorectal carcinoma samples, with successful establishment correlating in univariate analysis with higher tumor grading and advanced nodal status. Multivariate analysis identified nodal involvement as an independent predictor of successful in vitro model establishment. These findings reflect the enrichment of biologically aggressive phenotypes among successfully adapted cultures.

Within the broader HROC collection, models encompass all major molecular subtypes of colorectal carcinoma, including chromosomal instability (CIN), CpG island methylator phenotype (CIMP), microsatellite stable (MSS), and microsatellite instability-high (MSI-H) tumors, as well as diverse mutational backgrounds affecting genes such as KRAS, BRAF, TP53, APC, and PIK3CA. HROC300 T2 M1 was generated in this rigorously annotated context, allowing integration with matched clinicopathological data and, where available, corresponding PDX material. As a low-passage, patient-derived colorectal carcinoma model, HROC300 T2 M1 is suited for studies of tumor biology, genotype-phenotype associations, and preclinical therapeutic testing within a precision oncology framework.